Protocols for treatment of major depressive disorder (MDD)
US9572807B2 · kind B2 · utility
4Cited by
3References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 15, 2015 |
| Grant date | Feb 21, 2017 |
| Priority date | — |
| Expiry date | Jun 15, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.